Literature DB >> 23159737

Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.

Irfan A Asangani1, Bushra Ateeq, Qi Cao, Lois Dodson, Mithil Pandhi, Lakshmi P Kunju, Rohit Mehra, Robert J Lonigro, Javed Siddiqui, Nallasivam Palanisamy, Yi-Mi Wu, Xuhong Cao, Jung H Kim, Meng Zhao, Zhaohui S Qin, Mathew K Iyer, Christopher A Maher, Chandan Kumar-Sinha, Sooryanarayana Varambally, Arul M Chinnaiyan.   

Abstract

Histone methyltransferases (HMTases), as chromatin modifiers, regulate the transcriptomic landscape in normal development as well in diseases such as cancer. Here, we molecularly order two HMTases, EZH2 and MMSET, that have established genetic links to oncogenesis. EZH2, which mediates histone H3K27 trimethylation and is associated with gene silencing, was shown to be coordinately expressed and function upstream of MMSET, which mediates H3K36 dimethylation and is associated with active transcription. We found that the EZH2-MMSET HMTase axis is coordinated by a microRNA network and that the oncogenic functions of EZH2 require MMSET activity. Together, these results suggest that the EZH2-MMSET HMTase axis coordinately functions as a master regulator of transcriptional repression, activation, and oncogenesis and may represent an attractive therapeutic target in cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159737      PMCID: PMC3547524          DOI: 10.1016/j.molcel.2012.10.008

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  54 in total

1.  EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.

Authors:  Alfred S L Cheng; Suki S Lau; Yangchao Chen; Yutaka Kondo; May S Li; Hai Feng; Arthur K Ching; Kin F Cheung; Hoi K Wong; Joanna H Tong; Hongchuan Jin; Kwong W Choy; Jun Yu; Ka F To; Nathalie Wong; Tim H-M Huang; Joseph J Y Sung
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

Review 2.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Isolation and functional characterization of murine prostate stem cells.

Authors:  Devon A Lawson; Li Xin; Rita U Lukacs; Donghui Cheng; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

4.  pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene.

Authors:  Yojiro Kotake; Ru Cao; Patrick Viatour; Julien Sage; Yi Zhang; Yue Xiong
Journal:  Genes Dev       Date:  2007-01-01       Impact factor: 11.361

Review 5.  Polycomb genes and cancer: time for clinical application?

Authors:  Francesco Crea; Elisa Paolicchi; Victor E Marquez; Romano Danesi
Journal:  Crit Rev Oncol Hematol       Date:  2011-11-22       Impact factor: 6.312

6.  Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Authors:  Olga P Berezovska; Anna B Glinskii; Zhijian Yang; Xiao-Ming Li; Robert M Hoffman; Gennadi V Glinsky
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

7.  Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells.

Authors:  Oren Ram; Alon Goren; Ido Amit; Noam Shoresh; Nir Yosef; Jason Ernst; Manolis Kellis; Melissa Gymrek; Robbyn Issner; Michael Coyne; Timothy Durham; Xiaolan Zhang; Julie Donaghey; Charles B Epstein; Aviv Regev; Bradley E Bernstein
Journal:  Cell       Date:  2011-12-23       Impact factor: 41.582

8.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.

Authors:  Thomas Ernst; Andrew J Chase; Joannah Score; Claire E Hidalgo-Curtis; Catherine Bryant; Amy V Jones; Katherine Waghorn; Katerina Zoi; Fiona M Ross; Andreas Reiter; Andreas Hochhaus; Hans G Drexler; Andrew Duncombe; Francisco Cervantes; David Oscier; Jacqueline Boultwood; Francis H Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

Review 9.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

10.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.

Authors:  Yutaka Kondo; Lanlan Shen; Alfred S Cheng; Saira Ahmed; Yanis Boumber; Chantale Charo; Tadanori Yamochi; Takeshi Urano; Koichi Furukawa; Bernard Kwabi-Addo; David L Gold; Yoshitaka Sekido; Tim Hui-Ming Huang; Jean-Pierre J Issa
Journal:  Nat Genet       Date:  2008-05-18       Impact factor: 38.330

View more
  62 in total

1.  Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report.

Authors:  Rajesh C Rao; May P Chan; Chris A Andrews; Alon Kahana
Journal:  Cell Oncol (Dordr)       Date:  2018-09-13       Impact factor: 6.730

Review 2.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

Review 3.  Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Authors:  Ian G Mills
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

4.  Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.

Authors:  John B Wojcik; Dylan M Marchione; Simone Sidoli; Anissa Djedid; Amanda Lisby; Jacek Majewski; Benjamin A Garcia
Journal:  Cancer Res       Date:  2019-03-21       Impact factor: 12.701

5.  AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.

Authors:  Ni Li; Wei Xue; Huairui Yuan; Baijun Dong; Yufeng Ding; Yongfeng Liu; Min Jiang; Shan Kan; Tongyu Sun; Jiale Ren; Qiang Pan; Xiang Li; Peiyuan Zhang; Guohong Hu; Yan Wang; Xiaoming Wang; Qintong Li; Jun Qin
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

6.  ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.

Authors:  Phillip L Palmbos; Lidong Wang; Huibin Yang; Yin Wang; Jacob Leflein; McKenzie L Ahmet; John E Wilkinson; Chandan Kumar-Sinha; Gina M Ney; Scott A Tomlins; Stephanie Daignault; Lakshmi P Kunju; Xue-Ru Wu; Yair Lotan; Monica Liebert; Mats E Ljungman; Diane M Simeone
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

7.  Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Authors:  Matthieu Schoenhals; Alboukadel Kassambara; Jean-Luc Veyrune; Jerome Moreaux; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 8.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

9.  EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Authors:  Heather M Moore; Maria E Gonzalez; Kathy A Toy; Ashley Cimino-Mathews; Pedram Argani; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2013-03-29       Impact factor: 4.872

Review 10.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.